Drew Ranieri
Stock Analyst at Morgan Stanley
(1.24)
# 3,729
Out of 5,122 analysts
170
Total ratings
45.65%
Success rate
-11.38%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $19.70 | +16.75% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $87.91 | +13.75% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $20.86 | +0.67% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $5.18 | +15.83% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $354.12 | +25.66% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $12.68 | +112.93% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.48 | +223.23% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $20.51 | +7.26% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $15.47 | -48.29% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $3.62 | +2,179.01% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $21.91 | +73.44% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $80.98 | +18.55% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.30 | +130.09% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $195.64 | +50.79% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $121.62 | +130.23% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.45 | -32.89% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $19.30 | +262.69% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $572.63 | -47.61% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $19.70
Upside: +16.75%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $87.91
Upside: +13.75%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $20.86
Upside: +0.67%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $5.18
Upside: +15.83%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $354.12
Upside: +25.66%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $12.68
Upside: +112.93%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.48
Upside: +223.23%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $20.51
Upside: +7.26%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $15.47
Upside: -48.29%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $3.62
Upside: +2,179.01%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $21.91
Upside: +73.44%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $80.98
Upside: +18.55%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.30
Upside: +130.09%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $195.64
Upside: +50.79%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $121.62
Upside: +130.23%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.45
Upside: -32.89%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $19.30
Upside: +262.69%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $572.63
Upside: -47.61%